The placebo-controlled, double-blind Phase 2a study expects to include around 50 patients of age 55-85 who have been diagnosed with mild Alzheimer’s disease.
Currently, MSDC-0160 is being examined in 330 type 2 diabetes patients in a Phase 2b study across 26 sites in the US.
MSDC president and chief scientific officer Jerry Colca said MSDC-0160 is a novel insulin sensitizer that modulates mitochondrial metabolism.
"This study will help us determine if MSDC-0160 affects glucose utilization in specific regions of the brain and determine the feasibility of conducting future large-scale clinical studies in patients with mild Alzheimer’s disease," Colca said.